PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry – FDA

Опубликовано 3 октября, 201817 декабря, 2018 frozencat

Обновление руководства FDA:

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Руководство замещает Adaptive Design Clinical Trials for Drugs and Biologics – 2010.

Рубрики: Блог

Навигация по записям

Предыдущая запись: Определение объема выборки для исследований биоэквивалентности с использованием компьютерного моделирования
Следующая запись: Работа с данными в IBM SPSS: присвоение меток переменным из другого источника

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

IMG-20170802-WA0016
IMG-20170807-WA0003
20180131 141109
20180815 184358
IMG-20170807-WA0009
20170730 183005
  • Human medicines European public assessment report (EPAR): Filsuvez, birch bark extract, Date of authorisation: 21/06/2022, Revision: 6, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-11
  • Human medicines European public assessment report (EPAR): Capecitabine Teva, capecitabine, Date of authorisation: 20/04/2012, Revision: 17, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-11
  • Safety & Availability (Biologics)
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-07-10 By FDA
  • UPDATED MEETING DATE AND PUBLIC PARTICIPATION INFORMATION: May 5, 2025 Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee Meeting Announcement - 05/05/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-10 By FDA
  • Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Date of authorisation: 14/06/2007, Revision: 53, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-10
  • Human medicines European public assessment report (EPAR): Xbryk, denosumab, Date of authorisation: 12/02/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-10
  • Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-10
  • Human medicines European public assessment report (EPAR): Avtozma, tocilizumab, Date of authorisation: 14/02/2025, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-10
  • Human medicines European public assessment report (EPAR): Temozolomide Sun, temozolomide, Date of authorisation: 13/07/2011, Revision: 21, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-10
  • Human medicines European public assessment report (EPAR): Plegridy, peginterferon beta-1a, Date of authorisation: 18/07/2014, Revision: 26, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-10
  • Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-10 By FDA
  • FDA Embraces Radical Transparency by Publishing Complete Response Letters
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-10 By FDA
  • Human medicines European public assessment report (EPAR): Arikayce liposomal, amikacin, Date of authorisation: 27/10/2020, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-10
  • Human medicines European public assessment report (EPAR): Evotaz, atazanavir,cobicistat, Date of authorisation: 13/07/2015, Revision: 15, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-10
  • Dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - Revision 1
    Source: EMA - Scientific guidelines (human and veterinary) Published on 2025-07-10
Предыдущие записи
Тема: Scaffold от Danny Cooper.